8-K: Eledon's Tegoprubart Shows Strong Safety, Advances to Phase 3

Eledon Pharmaceuticals announced positive Phase 2 trial results for tegoprubart in kidney transplant rejection prevention, highlighting a favorable safety profile and plans for Phase 3 development, alongside a preliminary cash balance of $93.4 million.

Summary

• Eledon Pharmaceuticals reported results from its Phase 2 BESTOW trial for tegoprubart, an anti-CD40L antibody, evaluating its efficacy and safety in preventing organ rejection in de novo kidney transplant patients.
• The trial demonstrated tegoprubart's potential to maintain excellent kidney function with a mean 12-month estimated glomerular filtration rate (eGFR) of approximately 69 mL/min/1.73 m² for patients remaining on treatment.
• Tegoprubart exhibited a favorable safety and tolerability profile, significantly reducing metabolic, neurologic, and cardiovascular toxicities commonly associated with tacrolimus, the current standard of care.
• Key safety improvements included dramatically lower rates of new-onset diabetes (1 in 47 vs. 1 in 6 for tacrolimus), tremor (1.6% vs. 25.0%), hypertension (15.9% vs. 25.0%), and delayed graft function (14.3% vs. 25.0%).
• While the primary efficacy endpoint (change in eGFR at 12 months) did not reach statistical significance, the company believes the achieved mean eGFR of 69 mL/min/1.73 m² is the highest reported to date in kidney transplant clinical trials for rejection prevention.
• The efficacy failure composite endpoint (death, graft loss, and biopsy-proven acute rejection) was 22% for tegoprubart versus 17% for tacrolimus, demonstrating non-inferiority within a 20% margin, which the company believes is sufficient for approvability if replicated in Phase 3.
• Eledon plans to advance tegoprubart into Phase 3 development following discussions with regulatory authorities.
• The company's estimated cash, cash equivalents, and short-term investments were approximately $93.4 million as of September 30, 2025, expected to fund operations to late 2026.

Sentiment

Score: 8

Explanation: The filing presents strong positive data regarding tegoprubart's safety profile and its potential to maintain high eGFR, leading to advancement into Phase 3. While the primary endpoint did not reach statistical significance, the overall clinical profile, particularly the non-inferiority on the composite endpoint and the company's confidence in approvability, indicates a highly positive outlook for the lead candidate. The cash runway to late 2026 also provides financial stability.

Positives

• Tegoprubart demonstrated a favorable safety and tolerability profile, substantially reducing metabolic, neurologic, and cardiovascular toxicities compared to tacrolimus.
• New-onset diabetes developed in approximately 1 in 47 patients receiving tegoprubart versus 1 in 6 receiving tacrolimus.
• Tremor was markedly lower in the tegoprubart group (1.6%) compared to the tacrolimus group (25.0%).
• Hypertension (15.9% vs. 25.0%), hypertensive crisis (1.6% vs. 7.8%), and heart failure (0% vs. 4.7%) all favored tegoprubart.
• Delayed graft function occurred less often with tegoprubart (14.3% vs. 25.0%) and required shorter dialysis (4.6 days vs. 6.1 days).
• Sepsis or bacteremia occurred less frequently in the tegoprubart arm (4.8% vs. 17.2%).
• Tegoprubart maintained strong renal function with a mean 12-month eGFR of approximately 69 mL/min/1.73 m², which the company believes is the highest reported to date in kidney transplant clinical trials for rejection prevention.
• Subgroup analyses showed higher eGFRs in nearly all tegoprubart subgroups, particularly living-related donor recipients (~72 mL/min/1.73 m² vs. 62 mL/min/1.73 m²) and high Kidney Donor Profile Index (KDPI > 35) transplants (~62 mL/min/1.73 m² vs. 53 mL/min/1.73 m²).
• The efficacy failure composite endpoint demonstrated non-inferiority for tegoprubart versus tacrolimus, which the company believes supports approvability if replicated in Phase 3.
• The company plans to advance tegoprubart into Phase 3 development, indicating confidence in the drug's potential.
• Estimated cash, cash equivalents, and short-term investments of $93.4 million as of September 30, 2025, are expected to fund operations to late 2026.

Negatives

• The primary efficacy endpoint, change in eGFR at 12 months post-transplant, did not reach statistical significance.
• The rate of acute rejection in all biopsies was higher in the tegoprubart group (20.6%) compared with the tacrolimus group (14.1%).

Risks

• Risks relating to the safety and efficacy of drug candidates.
• Risks relating to clinical development timelines, including interactions with regulators and clinical sites, as well as patient enrollment.
• Risks relating to costs of clinical trials and the sufficiency of the company's capital resources to fund planned clinical trials.
• Uncertainties relating to the completion of quarter-end closing procedures for financial statements for the quarter ended September 30, 2025.

Future Outlook

Eledon plans to advance tegoprubart into Phase 3 development following discussions with regulators on study design and data requirements. Insights from the Phase 2 BESTOW data set and the ongoing long-term extension study will be incorporated to optimize the Phase 3 protocol and strengthen the regulatory package. The company expects its current cash, cash equivalents, and short-term investments to fund operations to late 2026.

Management Comments

• David-Alexandre C. Gros, M.D., CEO of Eledon: "The Phase 2 BESTOW data results demonstrate tegoprubart's potential to maintain excellent kidney function while reducing the chronic metabolic, neurologic, and cardiovascular toxicities that burden patients on tacrolimus."
• David-Alexandre C. Gros, M.D., CEO of Eledon: "By pairing strong immunosuppressive efficacy with a differentiated safety profile, including dramatically lower rates of new-onset diabetes, tremor, and dialysis-requiring delayed graft function, tegoprubart represents a promising next-generation option for kidney transplant immunosuppression as we advance into Phase 3."
• Andrew Adams, M.D., Ph.D., Professor of Surgery and Chief, Division of Transplantation, University of Minnesota: "There remains a significant unmet need for safer alternatives to traditional tacrolimus-based immunosuppression regimens—options that can reduce harmful side effects without compromising efficacy."
• Andrew Adams, M.D., Ph.D.: "The Phase 2 results presented at ASN Kidney Week highlight the potential of tegoprubart to deliver strong graft function after kidney transplantation, while avoiding the long-term toxicities often associated with current standard of care."
• Andrew Adams, M.D., Ph.D.: "It's been more than a decade since we've seen true innovation in transplant immunosuppression. These data offer real hope that patients may soon have a transformative therapy that improves their health outcomes and overall quality of life."

Industry Context

The announcement addresses a significant unmet need in kidney transplantation for safer alternatives to traditional tacrolimus-based immunosuppression regimens. Current standard-of-care therapies, while effective in preventing rejection, are associated with chronic metabolic, neurologic, and cardiovascular toxicities that burden patients and impact their quality of life. Tegoprubart's differentiated safety profile, coupled with its ability to maintain strong renal function, positions it as a potential next-generation option that could transform patient outcomes and quality of life in the transplant community, where true innovation in immunosuppression has been lacking for over a decade.

Comparison to Industry Standards

• Tegoprubart demonstrated a significantly more favorable safety profile compared to tacrolimus, the current standard of care, across multiple toxicity measures including new-onset diabetes, tremor, hypertension, hypertensive crisis, heart failure, delayed graft function, and sepsis/bacteremia.
• The mean 12-month eGFR of approximately 69 mL/min/1.73 m² for tegoprubart is believed by the company to be the highest reported to date in kidney transplant clinical trials evaluating rejection prevention, suggesting a potentially superior outcome in maintaining renal function compared to historical benchmarks.
• In specific subgroups, tegoprubart showed higher eGFRs, such as ~72 mL/min/1.73 m² for living-related donor recipients compared to ~62 mL/min/1.73 m² for tacrolimus, and ~62 mL/min/1.73 m² for high KDPI (>35) transplants compared to ~53 mL/min/1.73 m² for tacrolimus, indicating potential advantages in these patient populations.
• The efficacy failure composite endpoint for tegoprubart (22%) demonstrated non-inferiority to tacrolimus (17%) using a 20% non-inferiority margin, suggesting comparable overall efficacy in preventing major adverse events despite a higher acute rejection rate in the tegoprubart group.

Stakeholder Impact

• Shareholders: Positive impact due to the advancement of the lead drug candidate, tegoprubart, into Phase 3 development, potentially increasing the drug's value and the company's long-term prospects.
• Patients: Potential for significantly improved health outcomes and quality of life due to a safer immunosuppression option with reduced metabolic, neurologic, and cardiovascular toxicities compared to current standard of care.
• Medical Community: Tegoprubart could represent a transformative therapy and a new standard for the prevention of kidney transplant rejection, addressing a long-standing unmet need for innovation in transplant immunosuppression.
• Employees: Continued development of the lead product provides stability and potential for growth within the company.

Next Steps

• Advance tegoprubart into Phase 3 development.
• Hold discussions with regulators on Phase 3 study design and data requirements.
• Incorporate insights from the Phase 2 BESTOW data set and the ongoing long-term extension study to optimize the Phase 3 protocol and strengthen the regulatory package.
• Host a conference call on November 7, 2025, to discuss the updated Phase 2 BESTOW clinical data.

Key Dates

Recommendation

The strong safety profile of tegoprubart, significantly reducing common toxicities associated with tacrolimus, addresses a critical unmet need in kidney transplantation. Despite the primary efficacy endpoint not reaching statistical significance, the company's confidence in the drug's approvability based on the non-inferiority of the efficacy failure composite endpoint and the decision to advance to Phase 3 are strong positive signals. The reported eGFR levels are also encouraging. For a clinical-stage biotech, advancing a lead candidate to Phase 3 with a differentiated safety profile and a clear path to market, supported by a sufficient cash runway, presents a compelling long-term investment opportunity, warranting a 'buy' recommendation for investors with a higher risk tolerance.

Keywords

Eledon Pharmaceuticals, ELDN, Tegoprubart, Kidney Transplant, Organ Rejection, Immunosuppression, Phase 2 BESTOW Trial, Clinical Trial Results, eGFR, CD40L antibody, Biotechnology, Pharmaceuticals, Transplantation, Drug Development, Renal Function, Safety Profile, Tacrolimus, New-onset Diabetes, Delayed Graft Function, Acute Rejection